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Background: Safe dose thrombolysis (SDT) has been shown to be highly effective in the treatment of moderate and severe pulmonary embolism 
(PE) while eliminating bleeding risks. The combination of SDT plus rivaroxaban has been recently reported to be a potent strategy in treating PE 
thereby drastically reducing duration of hospitalization. We hereby report our experience with this approach known as “Drip, Drug and Discharge”.
methods: Over a 15 month period we treated 119 patients with symptomatic PE with SDT and rivaroxaban. SDT consisted of 10 mg of tPA given as 
bolus followed by 40 mg infusion in 2 h. It was started in parallel with unfractionated heparin. Heparin was given for a total of 24 h and rivaroxaban 
started at 15 or 20 mg daily 2 h after termination of heparin infusion. There were 101 patients with moderate and 18 patients with severe PE.
Results: The mean follow-up was 14 ± 1 months.No bleeding occurred due to SDT in any patients. There were 22 patients who were switched to 
warfarin after 1 month chiefly due to cost issues. Recurrent venous thromboembolism occurred in 3 patients who were on warfarin but in no patient 
who was on rivaroxaban. There were 2 patients who died of cancer. The pulmonary artery systolic pressure dropped from 50±3 before to 31±4 mmHg 
within 30 h of SDT (p<0.001).The duration of hospitalization for patients presenting primarily for PE was 1.8 ± 0.8 days.
conclusions: SDT plus rivaroxaban is highly safe and effective in the treatment of moderate and severe PE leading to excellent early and 
intermediate term outcomes and early discharge. The concept of “Drip, Drug and Discharge” is poised to lead to a paradigm shift in the treatment of 
PE especially given the economic constraints surrounding today’s health care .
